Actively Recruiting
Assessment of FibroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Led by The Third People's Hospital of Chengdu · Updated on 2024-12-06
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the best way to use FibroScan, a non-invasive tool to evaluate liver fat and scarring, in Chinese people with obesity. This observational study focuses on understanding the best cut-off values for diagnosing metabolic dysfunction-associated steatotic liver disease (MASLD) in this population. The study addresses uncertainties about factors that might affect FibroScan results and aims to improve diagnosis accuracy. Participants will undergo a FibroScan examination followed by a liver biopsy within a week to compare results. This approach helps assess how well FibroScan diagnoses MASLD compared to biopsy results. The study observes patients who are scheduled for bariatric surgery and liver biopsy as part of their clinical care. During the study, researchers will collect data over approximately one year to evaluate diagnostic accuracy and determine optimal cut-off values for FibroScan in people with obesity. Participants will be monitored for liver health and related factors as part of routine clinical assessments. The study is led by The Third People's Hospital of Chengdu and does not involve experimental treatments, focusing instead on improving diagnostic methods.
CONDITIONS
Brief Title
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older who provided written informed consent
- Patients scheduled to undergo bariatric surgery and a liver biopsy for suspected MASLD
- Patients scheduled to undergo FibroScan examination
You will not qualify if you...
- Patients with ascites or who are pregnant
- Patients with any active implantable medical device such as a pacemaker or defibrillator
- Patients who have undergone liver transplantation
- Patients with cardiac failure and/or significant valvular disease
- Patients with haemochromatosis
- Patients who have refused liver biopsy or blood tests
- Patients with active malignancy or other terminal disease
- Patients participating in another clinical trial within the preceding 30 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 1 week
Participants undergo a FibroScan examination followed by a liver biopsy within a week.
2 visits (in-person)
Duration - Approximately 1 year
Participants are observed for diagnostic accuracy and cut-off values over the course of approximately 1 year.
Visits as scheduled for assessments
Trial Site Locations
Total: 1 location
1
The Third People's Hospital of Chengdu
Chengdu, Sichuan, China
Actively Recruiting
Research Team
P
Peisen Guo
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here